Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow

B.M. Ryan*, M.G.V.M. Russel, E. Langholz, R.W. Stockbrügger

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow.

Ryan BM, Russel MG, Langholz E, Stockbrugger RW.

Department of Gastroenterology, University Hospital Maastricht, Maastricht, The Netherlands.

Inflammatory bowel disease (IBD) is associated with an increased risk of developing intestinal cancer at sites of chronic inflammation. Aminosalicylates, including both sulfasalazine and mesalamine, are the most commonly prescribed anti-inflammatory agents prescribed in IBD. On balance, the body of literature to date suggests that aminosalicylates confer some protection against the development of colonic neoplasia in patients with IBD and in a variety of models, including in the noninflamed gut. This latter observation implies that aminosalicylates may be of chemopreventive value in normal as well as IBD individuals. The current review examines and gives an overview of the evidence from a variety of sources, including epidemiological, in vivo and in vitro studies that have investigated the potential anticancer effects of aminosalicylates
Original languageEnglish
Pages (from-to)1682-1687
Number of pages5
JournalAmerican Journal of Gastroenterology
Issue number8
Publication statusPublished - 1 Jan 2003

Cite this